What question did this study set out to answer?

This research aims to evaluate the role of MALT1 in the growth of adult T cell leukemia/lymphoma and the effects of a novel MALT1 protease inhibitor.

July 26, 2026iScienceOpen Access

The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial finds MALT1 activity essential for tumor growth in specific ATL models, suggesting targeted therapy implications.

This research aims to evaluate the role of MALT1 in the growth of adult T cell leukemia/lymphoma and the effects of a novel MALT1 protease inhibitor.
Developed CRD-1441551, a selective MALT1 protease inhibitor.
Evaluated antitumor effects in three ATL cell lines and five patient-derived xenograft models, noting sensitivity variations.
Analyzed therapeutic responses relative to MALT1 activation and NF-κB signaling.
CRD-1441551 demonstrated variable sensitivity: two models were highly responsive, three with modest responses, and three unresponsive.
Stronger responses linked to models exhibiting constitutive MALT1 activation and enhanced NF-κB signaling.
Findings indicate that targeting MALT1 could be beneficial for specific ATL subsets dependent on this pathway.

Kamiunten et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

July 26, 2026iScienceOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial finds MALT1 activity essential for tumor growth in specific ATL models, suggesting targeted therapy implications.

This research aims to evaluate the role of MALT1 in the growth of adult T cell leukemia/lymphoma and the effects of a novel MALT1 protease inhibitor.
Developed CRD-1441551, a selective MALT1 protease inhibitor.
Evaluated antitumor effects in three ATL cell lines and five patient-derived xenograft models, noting sensitivity variations.
Analyzed therapeutic responses relative to MALT1 activation and NF-κB signaling.
CRD-1441551 demonstrated variable sensitivity: two models were highly responsive, three with modest responses, and three unresponsive.
Stronger responses linked to models exhibiting constitutive MALT1 activation and enhanced NF-κB signaling.
Findings indicate that targeting MALT1 could be beneficial for specific ATL subsets dependent on this pathway.

Kamiunten et al. (2026) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark